ICCC today
$10.22+$0.03 (+0.29%)close Nov 12, 2026Trend
DailyUptrend (confirmed)
4 hourLeaning Bullish
1 hourStrong Bearish
15 minBearish
5 minConsolidating
Daily trend turns down below $9.25
Key levels
Resistance$10.88
Resistance$10.49
Support$9.98
Support$9.60
Latest news & SEC filings
EarningsImmuCell posts Q3 profit of $0.10 per share as revenue reaches $8.040M
EarningsImmuCell preliminary Q3 sales rise 46% to $8.0 million
All ICCC news →About ImmuCell
ImmuCell develops and produces biologic animal-health treatments, chiefly for very young cattle. Its main offering, First Defense, is made from colostrum taken from hyperimmunized cows and delivers antibodies that target the pathogens causing scours in calves; it ships in several dose formats, including single-dose and multi-dose options. The company also sells a test for somatic cell counts in milk. Its customers are mostly dairy and cattle-raising operations in the U.S. and Canada, with some sales abroad.
Based on the company's 10-K filed Mar 30, 2026.
Nasdaq · Healthcare
IMMUCELL CORP /DE/ (ICCC)
What Is the Price Target for ICCC?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is ICCC a Buy or Sell Right Now?
Thesis
- •Revenue growing 4.3% YoY with ACCELERATING trend — accelerating momentum.
- •SEC filings signal active product innovation — 2 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ICCC.
Start Free Trial →Is ICCC Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B, PEG
Fair Value
$-31.34
46
Moat Score
NARROW
7/9
Piotroski Score
4.2
Altman Z-Score
What Is Smart Money Doing with ICCC?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ICCC Growth Story
Revenue YoY
4.3%
3yr Revenue CAGR
14.2%
EPS Growth YoY
53.85%
FCF Growth YoY
1236.0%
Revenue Trend
ACCELERATING
Dark Pool Trades for ICCC
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ICCC, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:14:10 | $10.32 | 1,000 | $$10K | BUY |
| 19:33:12 | $10.19 | 1,000 | $$10K | BUY |
| 19:32:43 | $10.00 | 1,000 | $$10K | SELL |
| 15:39:53 | $10.18 | 1,000 | $$10K | BUY |
| 16:56:45 | $9.95 | 1,000 | $$10K | SELL |
5 dark pool trades shown · $$51K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for IMMUCELL CORP /DE/ (ICCC) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ICCC — frequently asked questions
What is ICCC stock price today?
IMMUCELL CORP /DE/ (ICCC) is at $10.22, up 0.29% (+$0.03) at the Nov 12, 2026 close.
Why is ICCC stock moving today?
Latest ICCC news — Nov 12, 2026: ImmuCell posts Q3 profit of $0.10 per share as revenue reaches $8.040M · Oct 13, 2026: ImmuCell preliminary Q3 sales rise 46% to $8.0 million
Did ICCC beat earnings?
ICCC last reported on Aug 13, 2026: EPS $0.20.
What is ICCC's P/E ratio?
ICCC trades at a P/E of 145.6 vs a Healthcare average of 17.7.
Does ICCC pay a dividend?
ICCC does not currently pay a dividend.
How much debt does ICCC have?
IMMUCELL CORP /DE/ reported $8M of debt and $9M of cash (Jun 30, 2026).
What are ICCC support and resistance levels?
Support: $9.98, $9.60, $9.25. Resistance: $10.49, $10.88, $11.67.
What are insiders doing with ICCC?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on ICCC?
Nov 12, 2026: ImmuCell posts Q3 profit of $0.10 per share as revenue reaches $8.040M · Oct 13, 2026: ImmuCell preliminary Q3 sales rise 46% to $8.0 million